(S)-Blebbistatin (S)-1 ( Figure 1 ) is a well-known and widely used micromolar inhibitor of myosin II. 1 Given the multiple roles of this protein in a diverse range of motility-based diseases, 2−7 it is a promising target for therapeutic intervention. We have previously reported on the feasibility of improving (S)-blebbistatin's myosin II inhibitory potency and physicochemical properties. 8 We have also generated and analyzed SAR data on D-ring modified analogs. 9 These studies have shown that D-ring modification enables fine-tuning of (S)-blebbistatin's physicochemical properties, but potency enhancement cannot be pursued in this manner.
8−12
Figure 1. State-of-the-art on SAR-information of the (S)-blebbistatin scaffold and present work. 8−14 In the present report, our search for improved activity focused on the impact of structural changes in ring A. Analysis of the co-crystal structure of (S)-blebbistatin (S)-1 bound to the metastable state of Dictyostelium discoideum myosin II (PDB: 1YV3) 15 shows that the residues in closest proximity to rings AB are Tyr261, Thr474, Tyr634, Gln637 and Leu641
( Figure 2 ). Extending the (aromatic) ring system in this part of the molecule therefore has potential to improve binding affinity through additional hydrophobic interactions and π-π stacking with Tyr261. Lucas-Lopez et al. previously reported that small-sized substituents are 3 of little influence at the C 5 , C 6 and C 7 positions, but are undesired at the C 8 position. 13, 14 In this study, we incorporated larger cyclic substituents fused at positions C 6 and C 7 . Analog (S)-2 was envisioned to accommodate π-π stacking with Tyr261. To overcome potential solubility issues associated with the latter compound, a more polar analog (S) (S)-Benzo[h]blebbistatin (S)-2 was prepared via a route that was optimized previously by us. 8, 9 The synthesis started from commercially available 3-amino-2-naphthoic acid (6) (Scheme 1), which was converted to methyl ester 7 upon treatment with sulfuric acid in MeOH (step (a), 96%). Reaction of pyrrolidinone 8 with POCl 3 and amine 7 resulted in a 75% conversion to amidine 9 and isolated yield of 65% (step (b)). Intramolecular ring closure of the latter compound was induced after deprotonation by LiHMDS (step (c)). Asymmetric α-hydroxylation of intermediate 10 using Davis' oxaziridine methodology yielded analog (S)-2
The synthesis of (S)-
required the preparation of precursor 16, which was synthesized in an analogous way as described by Showalter et al. (Scheme 2). 16 In short, nitration of methyl 3-methyl-4-nitrobenzoate (12) resulted in a 85:15 mixture of methyl 5-methyl-2,4-dinitrobenzoate (13) and its isomer methyl 3-methyl-2,4-dinitrobenzoate. Isolation of compound 13 out of this 4 mixture of isomers proved difficult. Efforts to purify it via normal phase and reversed phase automated flash chromatography both failed and initial recrystallization attempts in 2-propanol were not successful either. Recrystallization parameters (solvent volume, timing) appeared to be crucial and eventually we were able to isolate methyl 5-methyl-2,4-dinitrobenzoate (13) in 55% yield (step (a)). Condensation with reagent 14 gave enamine 15 was used as a benchmark. Dose-response curves are presented in Figure 3 and half-maximum 6 inhibitory concentrations (IC 50 ) are summarized in Table 1 . Extending the aromatic system of ring A of the blebbistatin scaffold ((S)-2 and (S)-3) did not result in improved binding affinity.
Scheme 2. Synthesis of (S)-(N-allyl-2,3-dihydro-1H)-pyrrolo[3,2-h]blebbistatin (S)-5, (S)-(2,3-dihydro-1H)-pyrrolo[3,2-h]blebbistatin (S)-4 and (S)-(1H)-pyrrolo[3,2-h]blebbistatin (S)-

Reagents and conditions: (a)
The aliphatic ring systems in analogs (S)-4 and (S)-5 too had a negative impact on myosin II inhibitory activity. Moreover, Table 1 
